Delcath Systems, Inc. filings document an interventional oncology company with Nasdaq-listed common stock and a liver-directed drug-device platform. Form 8-K reports furnish quarterly and annual financial results, preliminary results, Regulation FD presentations, product revenue for HEPZATO KIT and CHEMOSAT, clinical publication updates for CHOPIN, and board-authorized share repurchase activity.
The company’s proxy materials cover annual meeting governance, executive compensation, equity awards, and related shareholder voting disclosures. Delcath filings also identify its common stock, par value, trading symbol DCTH, and Nasdaq Capital Market listing, while formal exhibits provide press releases and corporate presentations used for operating, clinical, and capital-structure disclosures.